Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016

  • ID: 3939721
  • Drug Pipelines
  • 97 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • GlaxoSmithKline Plc
  • Green Cross Corporation
  • Merck & Co., Inc.
  • NAL Pharmaceuticals Ltd.
  • NanoViricides, Inc.
  • MORE
Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016

Summary

‘Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016’, provides an overview of the Varicella Zoster (HHV-3) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Varicella Zoster (HHV-3) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Varicella Zoster (HHV-3) Infections and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note - : Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections
- The report reviews pipeline therapeutics for Varicella Zoster (HHV-3) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Varicella Zoster (HHV-3) Infections therapeutics and enlists all their major and minor projects
- The report assesses Varicella Zoster (HHV-3) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Varicella Zoster (HHV-3) Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • GlaxoSmithKline Plc
  • Green Cross Corporation
  • Merck & Co., Inc.
  • NAL Pharmaceuticals Ltd.
  • NanoViricides, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Varicella Zoster (HHV-3) Infections Overview

Therapeutics Development

Pipeline Products for Varicella Zoster (HHV-3) Infections - Overview

Pipeline Products for Varicella Zoster (HHV-3) Infections - Comparative Analysis

Varicella Zoster (HHV-3) Infections - Therapeutics under Development by Companies

Varicella Zoster (HHV-3) Infections - Therapeutics under Investigation by Universities/Institutes

Varicella Zoster (HHV-3) Infections - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Varicella Zoster (HHV-3) Infections - Products under Development by Companies

Varicella Zoster (HHV-3) Infections - Products under Investigation by Universities/Institutes

Varicella Zoster (HHV-3) Infections - Companies Involved in Therapeutics Development

Astellas Pharma Inc.

Beijing Minhai Biotechnology Co., Ltd

Beijing Tiantan Biological Products Co., Ltd.

ContraVir Pharmaceuticals, Inc.

Epiphany Biosciences, Inc.

Foamix Pharmaceuticals Ltd.

GeneOne Life Science, Inc.

GlaxoSmithKline Plc

Green Cross Corporation

Merck & Co., Inc.

N & N Pharmaceuticals Inc.

NAL Pharmaceuticals Ltd.

NanoViricides, Inc.

ReceptoPharm, Inc.

Sinovac Biotech Ltd.

SK Chemicals Co., Ltd.

TSRL, Inc.

XBiotech Inc

Zydus Cadila Healthcare Limited

Varicella Zoster (HHV-3) Infections - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(measles + mumps + rubella + varicella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella + varicella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acyclovir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amenamevir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chickenpox vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FV-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLS-5100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-1437173A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes zoster vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HHV-3 vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

measles + mumps + rubella + varicella vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MG-1111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Shingles - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAL-3221 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAL-3223 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NBP-608 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RKP-00156 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPI-78M - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sattabacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Shingles - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSR-087 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

V-212 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

valomaciclovir stearate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

varicella zoster vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Varicella Zoster (HHV-3) Infections - Dormant Projects

Varicella Zoster (HHV-3) Infections - Discontinued Products

Varicella Zoster (HHV-3) Infections - Product Development Milestones

Featured News & Press Releases

Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM

Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles

Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug

Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study

Oct 27, 2015: GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over

Oct 26, 2015: Sinovac Receives Clinical Trial Approval for Varicella Vaccine Candidate

Sep 08, 2015: Clinical trial for Cardiff’s shingles treatment

Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain

Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial

Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied

Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN

Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint

Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant

Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles

Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Varicella Zoster (HHV-3) Infections, H2 2016

Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by Astellas Pharma Inc., H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016

aricella Zoster (HHV-3) Infections - Pipeline by Epiphany Biosciences, Inc., H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by GeneOne Life Science, Inc., H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by GlaxoSmithKline Plc, H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by Green Cross Corporation, H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by Merck & Co., Inc., H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by N & N Pharmaceuticals Inc., H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by NAL Pharmaceuticals Ltd., H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by NanoViricides, Inc., H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by ReceptoPharm, Inc., H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by Sinovac Biotech Ltd., H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by SK Chemicals Co., Ltd., H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by TSRL, Inc., H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by XBiotech Inc, H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Varicella Zoster (HHV-3) Infections - Dormant Projects, H2 2016

Varicella Zoster (HHV-3) Infections - Discontinued Products, H2 2016 84List of Figures

Number of Products under Development for Varicella Zoster (HHV-3) Infections, H2 2016

Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • GlaxoSmithKline Plc
  • Green Cross Corporation
  • Merck & Co., Inc.
  • NAL Pharmaceuticals Ltd.
  • NanoViricides, Inc.
  • MORE
Varicella Zoster (HHV-3) Infections pipeline therapeutics constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Varicella Zoster (HHV-3) Infections – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Varicella Zoster (HHV-3) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Varicella Zoster (HHV-3) Infections Varicella zoster (HHV-3) infection is caused by the member of the herpes virus family. It results in two diseases namely chickenpox and shingles. Chickenpox is characterized by rashes, fever, tiredness, headaches etc. Along with the symptoms associated with chickenpox, shingles is also characterized by blisters and gastrointestinal problems. The predisposing factors are exposure direct contact with infected surface or organism and weakened immune system. The disease may be diagnosed by the examination of typical rashes associated with the infection. The disease may be controlled by medication such as antiviral and immunotherapies. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 4, 4, 2, 11 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Varicella Zoster (HHV-3) Infections and features dormant and discontinued projects. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Astellas Pharma Inc.
Beijing Minhai Biotechnology Co., Ltd
Beijing Tiantan Biological Products Co., Ltd.
ContraVir Pharmaceuticals, Inc.
Epiphany Biosciences, Inc.
Foamix Pharmaceuticals Ltd.
GeneOne Life Science, Inc.
GlaxoSmithKline Plc
Green Cross Corporation
Merck & Co., Inc.
N & N Pharmaceuticals Inc.
NAL Pharmaceuticals Ltd.
NanoViricides, Inc.
ReceptoPharm, Inc.
Sinovac Biotech Ltd.
SK Chemicals Co., Ltd.
TSRL, Inc.
XBiotech Inc
Zydus Cadila Healthcare Limited
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll